Клинико-социальная и фармакоэкономическая оценка антидепрессивной терапии эсциталопрамом
И. Я. Гурович, Alexander B. Shmukler, Е.Б. Любов et al. · Социальная и клиническая психиатрия · 2007
Subjects: a random group of patients (N=31) with pronounced depressive symptoms within categories of recurrent depression (58,1%), schizophrenia (16,1%) and schizoaffective disorder (25,8%). The severity of symptoms was measured by Hamilton Depression Scale (first 17 items) and Montgomery Asberg Depression Rating Scale. The parameters of social functioning and quality of life were assessed with the help of the EuroQol Scale and original checklist for evaluation of social functioning and quality of life. The patients' condition was evaluated before entering this investigation and every week afterwards during six weeks of treatment, and later on every month. The total duration of treatment was 6 months. Statistical data were processed with the help of the Statistica for Windows, version 6.0. In the analysis of the data the authors applied LOCF-method. They also performed pharmacoeconomic analysis. Economic effect of using cipralex as an alternative to traditional antidepressant (amitriptyline) in the subpopulation of patients with depressive disorder with high risk of relapse has been proven with regard for social perspective of the patient (maintaining capacity for work). Rather fast initial response, easy determining the minimal treatment dose, good tolerability, safety and efficacy for depressions varying in structure and severity, as well as its potential in improving social functioning and quality of life and saving resources make cipralex (Escitalopram) a first-choice antidepressive medication.
Cited by 0 works.